HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings

Key Points

• HC Wainwright raised Tenaya Therapeutics’ FY2026 EPS estimate to a loss of $0.37 per share from a previous estimate of $0.51, compared with the $0.40 consensus loss. The firm projects losses of $0.35 in FY2027 and $0.42 in FY2028.
• Tenaya reported a quarterly loss of $0.20 per share, missing the $0.07 consensus estimate, while revenue of $1.11 million fell well short of the $10 million expectation.
• Shares opened at $0.73, near their 52-week low, while analysts maintain a consensus “Moderate Buy” rating and a $4.00 price target. Institutional investors own 90.54% of the stock.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at HC Wainwright increased their FY2026 earnings per share estimates for Tenaya Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.37) for the year, up from their previous estimate of ($0.51). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Tenaya Therapeutics' FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.42) EPS.

TNYA has been the topic of a number of other reports. Wall Street Zen downgraded shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 6th. Weiss Ratings raised shares of Tenaya Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $4.00.

Tenaya Therapeutics Price Performance

NASDAQ:TNYA opened at $0.73 on Monday. The firm has a market cap of $157.72 million, a price-to-earnings ratio of -1.37 and a beta of 2.83. The company has a 50 day moving average price of $0.77 and a 200-day moving average price of $0.76. Tenaya Therapeutics has a 1-year low of $0.53 and a 1-year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $10.00 million.

Institutional Trading of Tenaya Therapeutics

Several institutional investors have recently bought and sold shares of TNYA. BlackRock Inc. purchased a new stake in shares of Tenaya Therapeutics in the second quarter valued at approximately $2,963,000. GSA Capital Partners LLP purchased a new position in shares of Tenaya Therapeutics during the 2nd quarter valued at approximately $1,973,000. Mirador Capital Partners LP lifted its position in shares of Tenaya Therapeutics by 2.0% during the 2nd quarter. Mirador Capital Partners LP now owns 905,097 shares of the company's stock valued at $669,000 after buying an additional 18,180 shares in the last quarter. Renaissance Technologies LLC grew its stake in Tenaya Therapeutics by 100.6% in the 1st quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company's stock valued at $2,571,000 after acquiring an additional 1,862,894 shares during the period. Finally, Integrity Wealth Solutions LLC acquired a new stake in Tenaya Therapeutics in the 1st quarter valued at $27,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source